Pharmaceutical Science Advances最新文献

{"title":"Phytochemical analysis and evaluation of the antibacterial and antibiotic potentiation activities of the aqueous extract of Cordia oncocalyx Allemão (Boraginaceae)","authors":"José Thyalisson da Costa Silva ,&nbsp;José Jailson Lima Bezerra ,&nbsp;Talysson Felismino Moura ,&nbsp;Rafael Pereira da Cruz ,&nbsp;Maraiza Gregorio de Oliveira ,&nbsp;Adrielle Rodrigues Costa ,&nbsp;Felicidade Caroline Rodrigues ,&nbsp;João Arthur de Oliveira Borges ,&nbsp;Terezinha Raila Ramos de Sousa ,&nbsp;Maria Flaviana Bezerra Morais-Braga ,&nbsp;Henrique Douglas Melo Coutinho ,&nbsp;José Weverton Almeida-Bezerra","doi":"10.1016/j.pscia.2024.100042","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100042","url":null,"abstract":"<div><p>The global antibiotic resistance crisis highlights the inappropriate use of medicines by the population and the lack of development of new antimicrobial agents. According to various studies, natural products are promising alternatives for combating bacterial resistance and treating infectious diseases. Accordingly, the present study aimed to analyze the chemical composition and evaluate the antibacterial and antibiotic potential of an aqueous extract of <em>Cordia oncocalyx</em> Allemão (AECO). Phytochemical analyses were performed using high-performance liquid chromatography equipped with a diode array detector (HPLC-DAD). The minimum inhibitory concentration (MIC) was used to evaluate the antibacterial activity of <em>C. oncocalyx</em> against conventional and multidrug-resistant (MDR) bacterial strains (<em>Escherichia coli, Pseudomonas aeruginosa</em>, and <em>Staphylococcus aureus</em>). According to HPLC-DAD analysis, the following compounds could be identified in the aqueous extract of <em>C. oncocalyx</em>: luteolin (3.07 ± 0.04 mg/g), caffeic acid (1.05 ± 0.03 mg/g), ellagic acid (0.62 ± 0.05 mg/g), and quercetin (0.58 ± 0.01). AECO did not exhibit antibacterial activity when administered alone (MIC &gt;512 μg/mL). However, when combined with gentamicin, ampicillin, and norfloxacin, AECO potentiated the action of these antibiotics against the multi-resistant strains of <em>P. aeruginosa</em> and <em>S. aureus</em>. Although clinical relevance was not revealed by the <em>in vitro</em> tests against pathogenic bacteria, AECO can combined with commercial antibiotics to improve their antibacterial effects. Future studies focusing on the mechanisms of action of the compounds isolated from <em>C. oncocalyx</em> and toxicological tests are fundamental.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000084/pdfft?md5=3b5fd055b0939ece2db4bd95252fb6b5&pid=1-s2.0-S2773216924000084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rational design of siRNA-based delivery systems for effective treatment of brain diseases","authors":"Dailin Lu ,&nbsp;Yonghang Sun ,&nbsp;Yuxia Luan,&nbsp;Wenxiu He","doi":"10.1016/j.pscia.2024.100041","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100041","url":null,"abstract":"<div><p>Effective clinical methods are urgently required to treat brain diseases. Small interfering RNAs (siRNAs) are promising in the treatment of brain diseases because of their ability to target and specifically silence genes associated with disease progression. However, their effectiveness is hindered by physiological barriers such as enzymatic degradation, the blood-brain barrier, and the blood-brain tumor barrier, severely restricting them from reaching the desired target sites. The development of nanotechnology has made the effective delivery of siRNAs to the brain possible. This is accomplished by encapsulating siRNAs in cationic polymers, liposomes, or micelles to improve their stability and targeting efficiency. In this review, we first analyzed the limitations of siRNA delivery in brain diseases such as brain tumors, stroke, and neurodegenerative diseases. Next, we summarized how nanotechnology can offer a solution by enabling effective siRNA delivery to the brain and improving the intracellular transfection efficiency of siRNA. Finally, we discussed the challenges and future advances of siRNA-based delivery systems to facilitate their clinical translation. This review emphasizes the importance of overcoming physiological barriers associated with siRNA delivery and highlights recent advances in the rational design of siRNA-based delivery systems for the effective treatment of brain diseases.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000072/pdfft?md5=8c06ff13b971cd909de39b050bf76bc3&pid=1-s2.0-S2773216924000072-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WN1703 alleviates gout symptoms via inflammatory signaling pathways in an acute gout rat model","authors":"Fuyao Liu,&nbsp;Xiaodan Lu,&nbsp;Lei Zhang,&nbsp;Jing Li","doi":"10.1016/j.pscia.2024.100039","DOIUrl":"10.1016/j.pscia.2024.100039","url":null,"abstract":"<div><p>We previously synthesized the xanthine oxidoreductase (XOR) inhibitor WN1703. In addition to showing XOR inhibitory effects, WN1703 also showed anti-inflammatory effects in a rat hyperuricemia model. Here, we studied WN1703's anti-inflammatory effects on gout and explored the underlying mechanisms. Tohoku Hospital Pediatrics-1 (THP-1) cells were stimulated by lipopolysaccharide/interferon-γ/monosodium urate (MSU). The levels of inflammatory cytokines in the supernatant and protein expression in THP-1 cells were detected using enzyme-linked immunosorbent assay (ELISA) kits and western blotting, respectively, to verify the inhibitory effects of WN1703 and its mechanism. Potassium oxonate, hypoxanthine, and MSU were administered to establish a hyperuricemia rat model complicated by acute gouty arthritis. At 1–24 h after MSU injection, the degree of ankle swelling was recorded to compare the anti-inflammatory effects at each time point. The potential mechanism was further explored using immunohistochemistry and ELISA. WN1703 significantly downregulated expression of nucleotide-binding oligomerization domain-like receptor thermal protein domain associated protein 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), caspase-1, toll-like receptor-4 (TLR4), myeloid differentiation primary response protein 88 (MyD88), nuclear factor-kappa B (NF-κB), and relevant cytokine levels in THP-1 cells. Identical doses of WN1703 and febuxostat had comparable effects on these proteins and cytokines. In the gout rats, the same dose of WN1703 and febuxostat showed equivalent inhibitory effects on NLRP3, ASC, and NF-κB; however, WN1703 showed weaker impacts on alleviating ankle swelling than febuxostat showed. In conclusion, WN1703 showed significant anti-inflammatory effects in hyperuricemic rats with acute gout. Such effects were related to the inhibition of the NLRP3/ASC/Caspase-1 and TLR4/MyD88/NF-κB signaling pathways, thereby downregulating inflammation-related protein expression and decreasing inflammatory cytokine secretion.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100039"},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000059/pdfft?md5=827dd9ffb0fdf9527799da1e715215a1&pid=1-s2.0-S2773216924000059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140401673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent progresses in combination cancer therapy using cyanine dye-based nanoparticles","authors":"Qian An ,&nbsp;Si-Rui Xiang ,&nbsp;You-Quan Zou","doi":"10.1016/j.pscia.2024.100040","DOIUrl":"10.1016/j.pscia.2024.100040","url":null,"abstract":"<div><p>Surgical resection, radiotherapy, and chemotherapy are traditional methods for cancer treatment. With the development of materials science, photodynamic, photothermal, and sonodynamic therapies have been established over the past few years. Despite these advances, the development of novel and efficient cancer treatment protocols remains highly desirable. Recently, combination therapy has emerged as a powerful tool for achieving this goal. In this context, cyanine-nanoparticles have attracted considerable interest. Cyanine dyes have high molar absorptivity, narrow absorption/emission bands, and also excellent biocompatibility. This has meant that they have been widely used in biomedical imaging and therapy. Cyanine nanoparticles assembled from cyanine dyes and amphiphilic polymers or liposomes are endowed with high biocompatibility and long-term circulation for cancer combination therapy. A plethora of cyanine–nanoparticle-based combination therapy systems have been reported, and research in this discipline continues to expand. In this review, we aim to summarize recent advances in the combination therapy of cancers using cyanine nanoparticles over the last five years (i.e., from 2018 to 2023), with an emphasis on the structures of cyanine dyes, design concepts, and combination strategies. Personal insights and challenges in this field are also discussed. We expect that this review will inspire creative progress in combination therapies based on cyanine nanoparticles and facilitate the investigation of future clinical applications.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000060/pdfft?md5=dd24426ea65b5644321f1dc848ea95f1&pid=1-s2.0-S2773216924000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140406373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The most recent advances in liquisolid technology: Perspectives in the pharmaceutical industry","authors":"Yaseen Hussain ,&nbsp;Jinghao Cui ,&nbsp;Amos Dormocara ,&nbsp;Haroon Khan","doi":"10.1016/j.pscia.2024.100038","DOIUrl":"10.1016/j.pscia.2024.100038","url":null,"abstract":"<div><p>Hydrophobic drugs exhibit altered bioavailability and pose other challenges at an industrial level due to their poor solubility and dissolution rates. In addition, poor flowability, compressibility, complex dosing schedules, and light-sensitivity problems associated with hydrophobic drugs have led to poor patient compliance. To overcome these problems at an industrial level, the liquid-solid technique is a promising approach for tackling such challenges. This study outlines the prementioned challenges related to hydrophobic drug candidates and introduces the liquisolid technique as a potential alternative using non-volatile water-miscible solvents, carrier agents, coating substances, and their subsequent applications in the pharmaceutical industry. Furthermore, this study highlights the role of liquisolid technology in achieving sustained-release kinetics, emphasizing its benefits in minimizing pH changes in drug release and enhancing photostability. The study aimed to explore the liquisolid technique as an important tool for improving drug delivery, overcoming solubility issues, and optimizing therapeutic outcomes. In addition, this manuscript holds significant importance by highlighting the applications and recent advances in liquisolid technology, focusing on industrial-level applications. Moreover, it is impressive that such a technique offers improved formulation options to enhance the safety and efficacy of therapy. Overall, this study serves as a valuable resource for researchers to overcome formulation challenges and optimize drug delivery in the pharmaceutical industry.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000047/pdfft?md5=28e7fad4f3931f73de3aa176469437b7&pid=1-s2.0-S2773216924000047-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140273362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and research progress of oncolytic virus","authors":"Yingyu Chen ,&nbsp;Mengyuan Tao ,&nbsp;Xuwei Wu ,&nbsp;Zheng Tang ,&nbsp;Yinfu Zhu ,&nbsp;Kunxiang Gong ,&nbsp;Yinger Huang ,&nbsp;Wenbo Hao","doi":"10.1016/j.pscia.2024.100037","DOIUrl":"10.1016/j.pscia.2024.100037","url":null,"abstract":"<div><p>Oncolytic viruses (OVs) are natural or genetically recombinant viruses that selectively infect and kill tumor cells without affecting normal cell growth. As a novel type of immunotherapy, OVs have been shown to activate antitumor immune responses, regulate the tumor microenvironment, and enhance the efficacy of immune checkpoint inhibitors. In this review article, we discuss the latest research on the characteristics, antitumor mechanisms, and status of OV research. In terms of mechanism of action, after targeting tumor cells, OVs not only directly lyse tumor cells but also exert antitumor effects through indirect approaches. As an emerging cancer treatment, OVs face challenges that need to be overcome. Finally, we summarize the challenges and prospects for the future application of OVs.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000035/pdfft?md5=d88b2383a920ee72888d00114bd11969&pid=1-s2.0-S2773216924000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140275801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of lycorine hydrochloride against diabetic nephropathy in high-fat diet and streptozotocin-induced diabetic mice","authors":"Kai-Li Fang ,&nbsp;Xin-Yu Qi ,&nbsp;Qing-Tong Han ,&nbsp;Lu-Zhou Chen ,&nbsp;Xiao-Ning Wang ,&nbsp;Zhen-Peng Xu ,&nbsp;Lu-Qing Shang ,&nbsp;Tao Shen","doi":"10.1016/j.pscia.2024.100035","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100035","url":null,"abstract":"<div><p>Diabetic nephropathy (DN) poses a significant risk to individuals with diabetes. Inflammation plays a crucial role in DN pathogenesis. Lycorine hydrochloride (LH) is derived from <em>Lycoris radiata</em> (L'Hér.). This herb has been identified as a potent anti-inflammatory molecule. Further studies indicated that LH displayed therapeutic potential against metabolic disorders, renal dysfunction, and fibrosis in a high-fat diet and streptozotocin-induced (HFD/STZ)-induced DN mouse model. Mechanistically, LH mitigated renal inflammation in DN mice by targeting NF-κB pathways and the NLRP3 inflammasome verified by <em>in vivo</em> study. <em>In vitro</em>, LH inhibited NLRP3 inflammasome activation induced by nigericin (Ng), monosodium urate (MSU), and ATP, reduced caspase-1 activation, and IL-1β release. Additionally, LH suppressed the NF-κB IS-induced activation, prevented nuclear translocation of NF-κB, and subsequently reduced the expression of downstream proteins COX2 and iNOS. Collectively, these results indicated that LH primarily improved hyperglycemia-induced renal function by reducing inflammation by targeting NF-κB and NLRP3 inflammasome, implying it is a promising therapeutic agent for DN.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100035"},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000011/pdfft?md5=e5fb7692c1c50492d880fd4f179372d7&pid=1-s2.0-S2773216924000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive manufacturing in nano drug delivery systems","authors":"Md. Habibur Rahman ,&nbsp;Nilufar Yasmin Liza ,&nbsp;Khan Rajib Hossain ,&nbsp;Dipika Ramdas Kalambhe ,&nbsp;Md. Abu Shyeed ,&nbsp;Dilwar Hossain Noor","doi":"10.1016/j.pscia.2024.100036","DOIUrl":"10.1016/j.pscia.2024.100036","url":null,"abstract":"<div><p>The adoption of innovative mixing and fabrication technologies in the pharmaceutical industry has inspired research on nano-drugs and expanded the scope of study in the field. Researchers' interest in the recently discovered drug delivery nanoparticles has increased significantly. This interest is especially seen in the specific preparation of nanoparticles as drug carriers through the use of three-dimensional (3D) printing, a modern additive manufacturing (AM) technology. The benefits of 3D printing, especially at the nanoscale, make it an innovative technology that could revolutionize the pharmaceutical and regenerative medicine industries. The laborious creation of intricate structures made possible by nanoscale 3D printing brings up the possibility of developing nanomedicine and producing functioning tissues and organs. The uses of AM in nano drug delivery systems (NDDS) are highlighted in this study, with a focus on how it can improve drug release kinetics, enhance therapeutic efficacy, and minimize side effects. A new era of personalized medicine has begun with the development of patient-specific formulations made possible by the customization capabilities of 3D printing. This review discusses the various uses of AM in NDDS while addressing issues including scalability, biocompatibility, and regulatory concerns. This review highlights the developing integration between AM and nanotechnology in medicine delivery and discusses ongoing research activities and possible solutions. As this innovative technology develops further, it has the potential to completely change the pharmaceutical development field by providing fresh approaches to the complex problems of contemporary healthcare and advancing the ideas behind drug delivery.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000023/pdfft?md5=cf73c01823eaed30da7a3590cf259c58&pid=1-s2.0-S2773216924000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial peptides: A novel and promising arsenal against methicillin-resistant Staphylococcus aureus (MRSA) infections","authors":"Tope T. Odunitan ,&nbsp;Adegboye O. Oyaronbi ,&nbsp;Fakuade A. Adebayo ,&nbsp;Paul A. Adekoyeni ,&nbsp;Boluwatife T. Apanisile ,&nbsp;Tolu D. Oladunni ,&nbsp;Oluwatosin A. Saibu","doi":"10.1016/j.pscia.2023.100034","DOIUrl":"10.1016/j.pscia.2023.100034","url":null,"abstract":"<div><p>Despite years of research, technological advancements, and the widespread use of vaccines and antibiotics as tools to combat microbial threats to humans, methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) infections remain a serious threat to global healthcare systems. The challenge of MRSA is a result of the bacteria's remarkably rapid evolution and adaptation, building up a collection of resistance genes that defeat the mechanism of traditional antibiotics. Conventional antibiotics, including the most notable beta-lactam antibiotics, such as penicillin and cephalosporin, are increasingly inadequate against the rapid adaptability and resistance of MRSA. Consequently, the scientific community's therapeutic arsenal for battling MRSA infections is becoming increasingly limited, necessitating innovative interventions<strong>.</strong> Antimicrobial peptides (AMPs), with their precise targeting mechanisms and innate modifiability, have emerged as promising therapeutic agents. By selectively interrupting bacterial processes and boosting innate immunological responses, AMPs offer a multifaceted strategy. Modern biotechnological and bioinformatics advancements have enabled the refinement of AMPs for improved efficacy. This comprehensive review delves into the intricate facets of MRSA pathogenicity, determinants of resistance, foundational tenets of peptide-based therapeutics, and recent scientific breakthroughs. A comprehensive analysis of the current research landscape, clinical implications, and persistent challenges underscores the potential of precisely tailored peptides as formidable weapons for counteracting the enduring threat of MRSA infections.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000326/pdfft?md5=8b1f8fd80d3b9643c6673743091d39bf&pid=1-s2.0-S2773216923000326-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139019029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of LibidUp-PE supplement on premature ejaculation: A randomized, placebo-controlled double-blind, crossover study","authors":"Jagadeesan M ,&nbsp;Adhisaya A ,&nbsp;T. Srinivasan ,&nbsp;Alphienes Stanley Xavier ,&nbsp;Pavithra Anandan ,&nbsp;Rajappan Chandra Satish Kumar ,&nbsp;Thangavel Mahalingam Vijayakumar","doi":"10.1016/j.pscia.2023.100033","DOIUrl":"https://doi.org/10.1016/j.pscia.2023.100033","url":null,"abstract":"<div><p>Premature ejaculation (PE) is the most common male sexual dysfunction. Selective serotonin reuptake inhibitors (SSRIs) are currently recommended for PE. However, the side effects of SSRIs, such as nausea, vomiting, and xerostomia, pose challenges to clinicians. Simultaneously, evidence indicates that psychological and behavioral treatments are often insufficient. LibidUp-PE is a nutraceutical designed to enhance sexual wellness and contains a combination of essential amino acids to boost stamina and vigor, addressing concerns like erectile dysfunction (ED). This study aimed to assess the safety and efficacy of LibidUp-PE in the treatment of PE. In this crossover, double-blind, placebo-controlled trial, 76 patients with PE were randomly divided into two groups. Group A received LibidUp-PE, whereas Group B received a placebo for 12 weeks. Following a 2-week wash-out period, the groups switched treatments for another 12 weeks. Intravaginal ejaculatory latency time (IELT) and post-ejaculatory refractory time (PERT) were measured as the primary outcomes to evaluate PE improvement. Plasma serotonin levels were measured as secondary parameters using enzyme-linked immunosorbent assay. The results showed that LibidUp-PE significantly improved the IELT score, increasing from 0.8 ± 0.2 min to 2.9 ± 1.1 min (<em>p</em> &lt; 0.01). PERT scores also significantly decreased from 15.8 ± 1.7 min to 5.6 ± 0.6 min after 12 weeks of LibidUp-PE treatment. Plasma serotonin levels significant increased from 93.6 ± 7.8 ng/mL to 168.4 ± 12.8 ng/mL (<em>p</em> &lt; 0.001) with LibidUp-PE treatment. In contrast, no significant improvements were observed in the placebo group. Notably, none of the participants withdrew their consent due to adverse reactions, which is indicative of the safety and tolerability of LibidUp-PE. In conclusion, 12-week treatment with LibidUp-PE demonstrated a beneficial effect in reducing PE symptoms, as reflected by improved IELT, reduced PERT, and increased plasma serotonin levels. Therefore, LibidUp-PE could be a promising solution for individuals with PE.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100033"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000314/pdfft?md5=3802bdfde5ac6739968ead8e62214a4c&pid=1-s2.0-S2773216923000314-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138738896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}